- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
This big pharmaceutical player's recent woes could be good news for its rivals, but it also poses risks for investors.
Eli Lilly built up much false hope by being far too bullish on its now-failed Alzheimer treatment, Cramer said.